[18F-FDG PET/CT in patients, treated for ovarian cancer, with elevated CA 125 levels but no evidence of recurrence on conventional imaging].
P
P
Bochev
Y
Y
Bocheva
A
A
Klisarova
S
S
Ivanov
J
J
Dancheva
B
B
Chaushev
D000328:Adult; D018394:CA-125 Antigen / Q000032:analysis*; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008875:Middle Aged; D064847:Multimodal Imaging; D009364:Neoplasm Recurrence, Local; D010051:Ovarian Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology / Q000517:prevention & control* / Q000601:surgery; D010053:Ovary / Q000000981:diagnostic imaging* / Q000473:pathology / Q000601:surgery; D049268:Positron-Emission Tomography; D014057:Tomography, X-Ray Computed
D018394:CA-125 Antigen; D019788:Fluorodeoxyglucose F18